Mycenax Biotech Inc.

永昕營運績效續旺 上半年EPS 0.32元 超越去年全年 產能與技術併進 跨足傳統生物藥、異體細胞治療與新世代療法

Mycenax and Cytiva Enable First Continuous Manufacturing Process Development Satellite Laboratory in Taiwan

Mycenax signs an MOU with CHO PHARMA, cooperating to expand the production and application of next-generation antibodies

Mycenax becomes Taiwan’s first CDMO company to complete the CHO-S and CHOZN® GS Cell Line Development with the Beacon® Optofluidic System

Mycenax Announces the Sale of LusiNEX to Gedeon Richter

MYCENAX SIGNS AGREEMENT WITH HUMMINGBIRD BIOSCIENCE FOR PRODUCTION OF ANTI-VISTA ANTIBODY HMBD-002 FOR CANCER CLINICAL TRIAL

Mycenax won the First Prize of Merck’s Advance Biotech Grant Program

Mycenax participates in the Biointernational convention in Philadelphia to actively expand business opportunity

Mycenax cooperates with Norwegian Vectron Biosolutions AS to create a high-volume microbiology platform for global CDMO

Pearl Fong, our vice president, was invited to have a speech in SNU BIO-MAX International Conference 2018.

Mycenax Biotech Inc. has been shortlisted as a finalist in the CPhI Pharma Awards!

BIOtech Japan 2018 is Completed and Mycenax Display Excellent Strength